Our hypothesis was that, in addition to DPP III overexpression, some DPP III mutations found in the human tumor genomes might be involved in the progression of cancer by changing its affinity for KEAP1, and subsequently affecting the KEAP1-NRF2 signaling pathway. Here, KEAP1 is linked to cancer.